Vitamin D Receptor Polymorphism

Compound Published Jul 4, 2026

Vitamin D Receptor Polymorphism

A gene variant that can shift vitamin D response.

Also known as

VDR polymorphism · VDR gene variant · VDR SNP · FokI · BsmI · ApaI · TaqI · rs2228570 · rs1544410 · rs7975232 · rs731236

If you act on the DNA result alone, you can miss the blood test that actually shows whether vitamin D needs attention.

4 min read · 875 words · 4 sources

In brief

In brief

Vitamin D receptor polymorphism is a common inherited variation in the VDR gene that can change how cells respond to active vitamin D, but it is not a vitamin D level test or a diagnosis.

  • VDR polymorphisms are named DNA spelling differences in the vitamin D receptor gene 2.
  • Genetic reports often list FokI, BsmI, ApaI, and TaqI as classic VDR variants 3.
  • A VDR result does not show vitamin D status; a 25(OH)D blood test does.

Deep dive

How it works

The VDR protein binds calcitriol, then partners with another receptor called retinoid X receptor. This pair attaches to specific control regions in DNA and changes the production of proteins involved in calcium transport, phosphate balance, immune signaling, and cell growth. FokI is notable because it can alter the starting point for building the receptor protein, while BsmI, ApaI, and TaqI are more often studied as markers near regulatory regions rather than direct protein changing switches.

When you'll see this

The term in the wild

Scenario

You upload raw DNA data and see VDR FokI rs2228570 marked in red.

What to notice

That result means you carry a particular version at one spot in the vitamin D receptor gene. It does not mean you are vitamin D deficient, and it does not prove you need a larger dose.

Why it matters

This prevents a common overreaction: treating a genetic marker as if it were a current lab abnormality.

Scenario

You are reading a vitamin D3 supplement page for Thorne Vitamin D and see general claims about supporting bones and immune function.

What to notice

Those claims relate to vitamin D biology in general. They do not tell you whether your VDR genotype makes that product better or worse for you.

Why it matters

A named supplement can still be reasonable, but the dose should be guided by intake, sun exposure, medical context, and 25(OH)D testing, not by a VDR label alone.

Scenario

A paper reports that TaqI or FokI was associated with better response to vitamin D supplementation.

What to notice

Look for the size and type of evidence. The 2022 review included 1,038 people and found signals for TaqI and FokI, but not for BsmI or ApaI.

Why it matters

This helps you read the finding as a possible response modifier, not a universal dosing rule.

Scenario

Your clinician orders vitamin D testing and your genetic report already mentions VDR.

What to notice

The blood test and the gene test answer different questions. The blood test shows your current vitamin D status. The gene test shows one inherited factor that may or may not affect response.

Why it matters

You can bring the genetic result to the appointment without letting it distract from the actionable lab value.

The full picture

The report names a receptor, not your vitamin D level

A direct to consumer genetic report may flag VDR FokI, BsmI, ApaI, or TaqI and then jump to a supplement suggestion. That jump is the problem. These names do not measure vitamin D in your blood. They name small inherited differences in the VDR gene, the gene that gives cells instructions for making the vitamin D receptor protein.

Here is the surprise: vitamin D does not do much by simply floating in the bloodstream. After your body converts it into its active hormone form, called calcitriol, it has to bind the vitamin D receptor inside cells. That receptor then helps switch certain genes up or down, especially genes involved in calcium and phosphate handling. A vitamin D receptor polymorphism is a common DNA spelling difference in that receptor gene. It is not the same as a rare disease causing mutation.

Why FokI gets more attention

The best known VDR polymorphisms have old lab names: FokI, BsmI, ApaI, and TaqI. Those names came from enzymes used in older DNA testing methods, not from what the variants do in the body. FokI is often discussed because it can affect where the cell starts building the receptor protein. In plain terms, one version can produce a receptor that is a few building blocks shorter than another version.

The other named variants are often used as location markers in the gene. They may travel with nearby DNA differences that matter, but many findings are population specific, small, or inconsistent. This is why one paper may link a VDR variant to an immune or metabolic outcome, while another paper does not. The variant is usually one small influence in a much larger picture that includes sun exposure, diet, body size, medications, kidney and liver function, inflammation, and baseline vitamin D level.

What the evidence can actually support

The most supplement relevant question is whether VDR variants change response to vitamin D. A 2022 systematic review and meta-analysis of eight studies with 1,038 people found no significant association for BsmI or ApaI, while TaqI variant carriers and the FokI FF genotype showed a better rise after supplementation in the included studies. That is interesting, but it is not strong enough to use a VDR result by itself to choose a high dose.

A separate meta-analysis published in 2023 reached a more cautious conclusion, reporting that vitamin D supplementation effects on blood 25-hydroxyvitamin D and metabolic traits were independent of the common VDR variants it studied. Taken together, the evidence is promising but mixed. VDR polymorphisms may help explain why people respond differently, but they do not replace ordinary clinical monitoring.

The one useful decision

If a genetic report says you have a VDR polymorphism, the strongest next step is not to change your dose from the DNA result. Get or review your 25-hydroxyvitamin D blood test, usually written as 25(OH)D, and adjust supplementation with a clinician using that number. The gene result may be context. The blood value is the current status report.

Myths vs reality

What people get wrong

Myth

If you have a VDR polymorphism, vitamin D supplements will not work for you.

Reality

Common VDR variants may slightly shift response in some groups, but they usually do not shut the system off. Many people with these variants still raise their 25(OH)D with ordinary vitamin D intake.

Why people believe this

Direct to consumer reports often turn small genetic associations into simple supplement instructions because simple instructions are easier to sell than uncertainty.


Myth

VDR polymorphism means the same thing as a VDR mutation disease.

Reality

A polymorphism is a common version in the population. Rare pathogenic VDR variants can cause vitamin D dependent rickets type 2A, which is a different medical category involving serious receptor dysfunction.

Why people believe this

Both are described as changes in the VDR gene, but genetics uses different words for common variation and disease causing variants. MedlinePlus Genetics separates normal VDR function from pathogenic VDR changes.


Myth

The enzyme style names, FokI, BsmI, ApaI, and TaqI, describe body systems or symptoms.

Reality

Those names come from lab enzymes used to recognize DNA patterns. They are labels for DNA testing landmarks, not descriptions of fatigue, immunity, bones, or mood.

Why people believe this

The named cause is the older restriction fragment length polymorphism method, often shortened to PCR-RFLP, which used restriction enzymes to cut DNA at specific patterns.

Why this keeps coming up

This keeps showing up because genetic reports and supplement advice often use it to explain why people may respond differently to vitamin D.

How to use this knowledge

A specific failure mode to avoid: do not stack high dose vitamin D with calcium just because a genetic report flags VDR. Vitamin D can raise calcium absorption, and dose decisions matter more in people with kidney disease, kidney stones, high calcium, sarcoidosis, or certain medications.

What to do with this

  • Use a 25(OH)D blood test to guide vitamin D decisions, not the gene result alone.
  • Treat FokI, BsmI, ApaI, and TaqI as common report labels, not proof of a problem.
  • If you see mixed research, assume the effect is small and not a dosing rule.
  • Do not use VDR status by itself to justify high dose vitamin D.

Frequently asked

Common questions

Should I test my VDR gene before taking vitamin D?

For most people, no. A 25(OH)D blood test is more useful because it shows your current vitamin D status, while VDR testing only shows one inherited factor that may have a small or uncertain effect.

Can VDR polymorphisms explain why my vitamin D level stays low?

They might be one contributor, but low intake, limited sun exposure, higher body fat, absorption problems, liver or kidney disease, and medication effects are usually more actionable places to look first.

Which VDR variants show up most often in research?

The classic four are FokI, BsmI, ApaI, and TaqI. Genetic reports may also show their reference numbers: rs2228570, rs1544410, rs7975232, and rs731236.

Does VDR status change whether I should use vitamin D2 or D3?

Current VDR polymorphism evidence does not give a reliable rule for choosing D2 versus D3. Product choice is usually based on dose, diet preference, clinician advice, and follow up blood levels.

Can I use VDR results to choose an immune support supplement?

Not as a stand alone reason. VDR biology is involved in immune signaling, but common polymorphisms do not prove that a specific immune supplement will help you.

Want personalized recommendations?

Show me what works for me